Selank
A synthetic heptapeptide analog of tuftsin examined in preclinical neuropharmacology, gene-expression, and neuroimmune signaling research models.
View Selank in the storeQuick answers
What is Selank?
Selank is a synthetic heptapeptide analog of tuftsin examined in preclinical neuropharmacology, gene-expression, and neuroimmune signaling research models. It is a synthetic heptapeptide (tuftsin analog) of 7 amino acids with a molecular weight of 751.88 g/mol and the formula C33H57N11O9.
How much published research cites Selank?
The Luvaminos Selank record cites 27 published references, dated 2001 to 2024. Each is listed on this page with a link to its source.
Does Luvaminos test Selank, and where is the certificate?
Yes. Every Selank lot Luvaminos sells is tested by Freedom Diagnostics Testing, PLLC, an independent laboratory. The current 5 mg lot, SELANK-10-001, measured 99.43% purity by HPLC and a net content of 5.20 mg, tested September 4, 2026. Its certificate is published at luvaminos.com/coa/SELANK-10-001.
What modifications does Selank carry?
Selank: Free termini; tuftsin (Thr-Lys-Pro-Arg) extended with a C-terminal Pro-Gly-Pro motif to confer protease resistance. N-Acetyl Selank adds N-terminal acetylation as a further stability modification.
How is Selank powder stored?
Sealed Selank powder: -20°C, protected from light and moisture; stable long term. Protect from light.
How is Selank different from Semax?
Selank and Semax are different compounds: Selank has 7 amino acids, a molecular weight of 751.88 g/mol and formula C33H57N11O9; Semax has 7 amino acids, a molecular weight of 813.93 g/mol and formula C37H51N9O10S. Semax: C-terminal Pro-Gly-Pro tripeptide extension of the ACTH(4-7) core.
How is Selank different from Selank / Semax?
Selank is a single compound; Selank / Semax is a blend of Selank and Semax, with Selank as one of its 2 components. Selank has 7 amino acids and a molecular weight of 751.88 g/mol.
Molecular Profile
- Type
- Synthetic heptapeptide (tuftsin analog)
- Molecular formula
- C33H57N11O9
- Molecular weight
- 751.88 g/mol
- CAS number
- 129954-34-3
- Amino acids
- 7
- Sequence
- Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP)
- Modification
- Free termini; tuftsin (Thr-Lys-Pro-Arg) extended with a C-terminal Pro-Gly-Pro motif to confer protease resistance. N-Acetyl Selank adds N-terminal acetylation as a further stability modification.
Mechanism & Target Class
A linear heptapeptide analogue of the immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg), extended at the C-terminus with a Pro-Gly-Pro motif reported to confer resistance to peptidase cleavage. Research on the parent compound describes several studied mechanisms: concentration-dependent inhibition of enkephalin-degrading enzymes in human serum, examined in relation to endogenous enkephalin hydrolysis; modulation of GABAergic-system gene expression studied at the transcriptional level; effects on monoamine systems (serotonin, dopamine, norepinephrine) measured by HPLC in brain structures; and regulation of BDNF expression and cytokine/chemokine gene expression. N-Acetyl Selank is the N-terminally acetylated variant; its pharmacological properties are inferred from parent-compound studies, as no dedicated peer-reviewed literature exists for the acetylated form.
Storage & Handling
- Lyophilized
- -20°C, protected from light and moisture; stable long term.
- Handling
- Hydrophilic and water-soluble; protect from light.
Primary Database
References (27)
Reviews
1Deigin VI, Poluektova EA, Beniashvili AG, Kozin SA, Poluektov YM. (2022). Pharmaceutics
- 2
Kolomin T, et al. (2018). Protein Pept Lett
- 3
Kolomin TA, et al. (2019). Biology Bulletin
Clinical
4Panikratova YaR, et al. (2020). Doklady Biological Sciences
- 5
Medvedev VE, Tereshchenko ON, Israelyan AYu, Chobanu IK, Kost NV, Sokolov OYu, Myasoedov NF. (2014). Zh Nevrol Psikhiatr Im S S Korsakova
- 6
Zozulia AA, et al. (2008). Zh Nevrol Psikhiatr
- 7
Uchakina ON, et al. (2008). Zh Nevrol Psikhiatr
Primary research
8Filippenkov IB, Glazova NYu, Sebentsova EA, et al. (2024). Nanobiotechnology Reports
- 9
Konstantinopolsky MA, Chernyakova IV, Kolik LG. (2022). Bull Exp Biol Med
- 10
Kolik LG, Nadorova AV, et al. (2019). Bull Exp Biol Med
- 11
Povarov IS, Kondratenko RV, Derevyagin VI, Myasoedov NF, Skrebitsky VG. (2017). Bull Exp Biol Med
- 12
Filatova E, Kasian A, Kolomin T, Rybalkina E, Alieva A, Andreeva L, et al. (2017). Front Pharmacol
- 13
Volkova A, et al. (2016). Front Pharmacol
- 14
Kolomin T, et al. (2014). Molecular Immunology
- 15
Kolomin TA, et al. (2014). Neuroscience and Behavioral Physiology
- 16
Solov'ev VB, Gengin MT, et al. (2012). J Evol Biochem Physiol
- 17
Kolomin TA, Shadrina MI, Agniullin YaV, et al. (2010). Doklady Biochemistry and Biophysics
- 18
Andreeva LA, Ershov FI, et al. (2009). Vopr Virusol
- 19
Semenova TP, Kozlovskii II, Zakharova NM, Kozlovskaia MM. (2009). Eksp Klin Farmakol
- 20
Narkevich VB, et al. (2008). Eksp Klin Farmakol
- 21
Inozemtseva LS, Karpenko EA, Dolotov OV, et al. (2008). Doklady Biological Sciences
- 22
Semenova TP, Kozlovskaya MM, Zuikov AV, et al. (2008). Neuroscience and Behavioral Physiology
- 23
Zolotarev YuA, Sokolov OYu, Kost NV, et al. (2004). Russian Journal of Bioorganic Chemistry
- 24
Kozlovskaya MM, Kozlovskii II, Val'dman EA, Seredenin SB. (2003). Neuroscience and Behavioral Physiology
- 25
Sokolov OYu, Meshavkin VK, Kost NV, Zozulya AA. (2002). Bull Exp Biol Med
- 26
Kost NV, Sokolov OYu, Gabaeva MV, et al. (2001). Russian Journal of Bioorganic Chemistry
- 27
Kost NV, et al. (2001). Bull Exp Biol Med
Related compounds
Compared side by side